BR112015028115A2 - métodos e composições para o tratamento de câncer - Google Patents

métodos e composições para o tratamento de câncer

Info

Publication number
BR112015028115A2
BR112015028115A2 BR112015028115A BR112015028115A BR112015028115A2 BR 112015028115 A2 BR112015028115 A2 BR 112015028115A2 BR 112015028115 A BR112015028115 A BR 112015028115A BR 112015028115 A BR112015028115 A BR 112015028115A BR 112015028115 A2 BR112015028115 A2 BR 112015028115A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
cancer treatment
cancer
treatment
Prior art date
Application number
BR112015028115A
Other languages
English (en)
Other versions
BR112015028115B1 (pt
Inventor
Soucek Laura
Beaulieu Marie-Eve
Original Assignee
Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron filed Critical Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron
Priority to BR122020017819-1A priority Critical patent/BR122020017819B1/pt
Publication of BR112015028115A2 publication Critical patent/BR112015028115A2/pt
Publication of BR112015028115B1 publication Critical patent/BR112015028115B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112015028115-0A 2013-05-07 2014-05-07 Métodos e composições para o tratamento de câncer BR112015028115B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122020017819-1A BR122020017819B1 (pt) 2013-05-07 2014-05-07 Métodos e composições para o tratamento de câncer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13382167.8 2013-05-07
EP20130382167 EP2801370A1 (en) 2013-05-07 2013-05-07 Methods and compositions for the treatment of cancer
PCT/EP2014/059315 WO2014180889A1 (en) 2013-05-07 2014-05-07 Methods and compositions for the treatment of cancer

Publications (2)

Publication Number Publication Date
BR112015028115A2 true BR112015028115A2 (pt) 2017-10-17
BR112015028115B1 BR112015028115B1 (pt) 2023-11-21

Family

ID=48366303

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122020017819-1A BR122020017819B1 (pt) 2013-05-07 2014-05-07 Métodos e composições para o tratamento de câncer
BR112015028115-0A BR112015028115B1 (pt) 2013-05-07 2014-05-07 Métodos e composições para o tratamento de câncer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122020017819-1A BR122020017819B1 (pt) 2013-05-07 2014-05-07 Métodos e composições para o tratamento de câncer

Country Status (25)

Country Link
US (2) US10370434B2 (pt)
EP (4) EP2801370A1 (pt)
JP (2) JP6722103B2 (pt)
KR (1) KR102324116B1 (pt)
CN (1) CN105378084B (pt)
AU (1) AU2014264642B2 (pt)
BR (2) BR122020017819B1 (pt)
CA (1) CA2911863A1 (pt)
CY (1) CY1121849T1 (pt)
DK (1) DK2994533T3 (pt)
EA (2) EA202090683A3 (pt)
ES (1) ES2733515T3 (pt)
HK (2) HK1219756A1 (pt)
HR (1) HRP20191330T1 (pt)
HU (1) HUE045615T2 (pt)
IL (2) IL242483B (pt)
LT (1) LT2994533T (pt)
ME (1) ME03509B (pt)
MX (1) MX370792B (pt)
PL (1) PL2994533T3 (pt)
PT (1) PT2994533T (pt)
RS (1) RS59276B1 (pt)
SG (2) SG10201709101VA (pt)
SI (1) SI2994533T1 (pt)
WO (1) WO2014180889A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2801370A1 (en) 2013-05-07 2014-11-12 Fundació Privada Institut d'Investigació Oncològica de Vall Hebron Methods and compositions for the treatment of cancer
WO2017136534A1 (en) * 2016-02-03 2017-08-10 Kennesaw State University Researcha And Service Foundation, Inc. Signal molecules as cell penetration agents
WO2017190061A1 (en) * 2016-04-29 2017-11-02 The University Of Chicago Synthetic dna binding domain peptides and uses thereof
EP3269734A1 (en) 2016-07-15 2018-01-17 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Methods and compositions for the treatment of cancer
CN106591335A (zh) * 2016-11-08 2017-04-26 安徽省农业科学院水稻研究所 一种密码子植物化改造的LbCpf1基因及其应用
KR20200052350A (ko) * 2017-09-08 2020-05-14 아이디피 디스커버리 파마, 에스.엘. 다발성 골수종의 새로운 치료
EP3717506A4 (en) * 2017-11-29 2021-09-01 Agency for Science, Technology and Research CHEMICAL MOLECULE FOR TARGETING C-MYC IN CELLS
CA3096670A1 (en) * 2018-04-09 2019-10-17 Board Of Regents, The University Of Texas System Therapeutic targeting of oncogenes using exosomes
JP2022517236A (ja) * 2019-01-12 2022-03-07 ザ・メソジスト・ホスピタル 自己組織化ペプチドナノ粒子およびその使用
WO2020187998A1 (en) * 2019-03-19 2020-09-24 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
TWI829893B (zh) 2019-03-19 2024-01-21 瓦爾希伯倫私人腫瘤研究基金會 診斷肺癌的方法
KR102221227B1 (ko) 2019-05-07 2021-03-03 김영화 공급자 연동과 다국어 지원 기능을 구비한 쇼핑몰 플랫폼 제공 장치 및 그 방법
WO2021041953A1 (en) * 2019-08-30 2021-03-04 The Regents Of The University Of California Gene fragment overexpression screening methodologies, and uses thereof
CN115925975A (zh) * 2022-08-03 2023-04-07 山东大学 一种靶向肿瘤干细胞的car-mφ体内外编辑制备方法以及其应用
EP4361633A1 (en) 2022-10-25 2024-05-01 Peptomyc, S.L. Method for predicting response to a cancer treatment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US5322801A (en) 1990-04-19 1994-06-21 The General Hospital Corporation Protein partner screening assays and uses thereof
EP0633933A1 (en) 1992-03-23 1995-01-18 Imperial Cancer Research Technology Limited Leucine zippers
EP1342781A1 (en) * 2002-03-09 2003-09-10 ARTEMIS Pharmaceuticals GmbH Recombinase fusion protein with enhanced cellular uptake
GB0413730D0 (en) 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20110160159A1 (en) * 2009-09-15 2011-06-30 John Ryan Treatment of cancer
DE102009052866A1 (de) 2009-11-13 2011-05-19 Bizerba Gmbh & Co. Kg Schneidemaschine
EP2544686A4 (en) 2010-02-05 2013-06-26 Whitehead Biomedical Inst COMBINED METHODS FOR THE TREATMENT OF DISEASES
AU2011267078B2 (en) 2010-06-14 2014-09-25 F. Hoffmann-La Roche Ag Cell-penetrating peptides and uses therof
US9241920B2 (en) * 2011-10-27 2016-01-26 New York University Inhibition of c-Myc ubiquitination to prevent cancer initiation and progression
EP2801370A1 (en) 2013-05-07 2014-11-12 Fundació Privada Institut d'Investigació Oncològica de Vall Hebron Methods and compositions for the treatment of cancer

Also Published As

Publication number Publication date
SG10201709101VA (en) 2017-12-28
US10370434B2 (en) 2019-08-06
AU2014264642B2 (en) 2020-09-17
EP3338789A1 (en) 2018-06-27
PL2994533T3 (pl) 2020-03-31
US20190382468A1 (en) 2019-12-19
SI2994533T1 (sl) 2019-09-30
EA035463B1 (ru) 2020-06-19
KR20160013058A (ko) 2016-02-03
AU2014264642A1 (en) 2015-11-19
WO2014180889A1 (en) 2014-11-13
EP2994533B1 (en) 2019-05-01
JP2019147792A (ja) 2019-09-05
ES2733515T3 (es) 2019-11-29
BR112015028115B1 (pt) 2023-11-21
HRP20191330T1 (hr) 2019-10-18
CA2911863A1 (en) 2014-11-13
ME03509B (me) 2020-04-20
IL273090A (en) 2020-04-30
HK1219756A1 (zh) 2017-04-13
CY1121849T1 (el) 2020-07-31
HK1251494A1 (zh) 2019-02-01
EA201690159A1 (ru) 2016-05-31
EP2801370A1 (en) 2014-11-12
LT2994533T (lt) 2019-08-12
SG11201509131VA (en) 2015-12-30
CN105378084A (zh) 2016-03-02
EA202090683A2 (ru) 2020-06-30
EP2994533A1 (en) 2016-03-16
BR122020017819B1 (pt) 2023-11-21
PT2994533T (pt) 2019-08-05
EA202090683A3 (ru) 2020-09-30
KR102324116B1 (ko) 2021-11-11
MX370792B (es) 2020-01-08
JP6722103B2 (ja) 2020-07-15
JP6790148B2 (ja) 2020-11-25
RS59276B1 (sr) 2019-10-31
DK2994533T3 (da) 2019-07-01
US11339205B2 (en) 2022-05-24
IL242483B (en) 2020-03-31
HUE045615T2 (hu) 2020-01-28
JP2016520056A (ja) 2016-07-11
US20160122415A1 (en) 2016-05-05
EP3545966A1 (en) 2019-10-02
CN105378084B (zh) 2019-07-05
MX2015015518A (es) 2016-07-21
IL273090B (en) 2022-06-01
WO2014180889A8 (en) 2015-06-18

Similar Documents

Publication Publication Date Title
IL273090B (en) Methods and preparations for the treatment of cancer
IL245281A0 (en) Methods and preparations for the treatment of cancer
BR112017011771A2 (pt) métodos e composições para o tratamento de câncer
BR112014032105A2 (pt) método para o tratamento de câncer
ZA201505390B (en) Compositions and methods for treating pests
DK3076976T3 (da) Fremgangsmåder til behandling af cancer
BR112014031806A2 (pt) método para tratamento de câncer positivo para gd2
BR112015025408A8 (pt) combinações de drogas para tratar câncer
IL244353A0 (en) Compounds and use for cancer treatment
HK1213817A1 (zh) 治療癌症的方法
BR112014022694A2 (pt) novos métodos e composições para o tratamento de doença
DK3052102T3 (da) Sammensætninger til behandling af cancere
EP3004395A4 (en) Compositions and methods for treating cancer
SG11201510300RA (en) Compositions and methods for treating skin
HK1219513A1 (zh) 治療癌症的方法
BR112013028890A2 (pt) composições e métodos para o tratamento de câncer
DK3071192T3 (da) Curcuphenolforbindelse til anvendelse i behandling af cancer
DK2976101T3 (da) Behandlingsfremgangsmåde
EP2970510A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES
EP2984185A4 (en) Methods and compositions for treating cancer
EP2971044A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
DK3041506T3 (da) Behandlingsfremgangsmåde
ES1079026Y (es) Candelabro para tanatorio o similar
GB201300546D0 (en) Cancer Treatment
GB201302474D0 (en) Compositions and methods for treating biofilms

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/05/2014, OBSERVADAS AS CONDICOES LEGAIS